Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Metabolyz vs Primary Clinic (Direct GLP)

Metabolyz
Graded #339

Lower grade

vs+9.100000000000001
Primary Clinic (Direct GLP)
Graded #145

Higher grade

The verdict

Primary Clinic (Direct GLP) takes it — 68.7/100 to 59.6/100.

Primary Clinic (Direct GLP) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Primary Clinic (Direct GLP) is a Direct Primary Care membership rather than the usual direct-to-consumer GLP-1 marketplace.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePrimary Clinic (Direct GLP) +33
45
78
Dose & formulationPrimary Clinic (Direct GLP) +14
40
54
Clinical oversightMetabolyz +6
81
75
Labs & monitoringPrimary Clinic (Direct GLP) +13
63
76
FulfillmentMetabolyz +13
86
73
Contract termsMetabolyz +14
55
41
Metabolyz · left barPrimary Clinic (Direct GLP) · right bar

The numbers

MetricMetabolyzPrimary Clinic (Direct GLP)
WeighScore59.6/10068.7/100
GradeCC
Scorecard rank#339#145
SemaglutideNot disclosed$65/mo (0.25 mg dose, promotional rate, compounded)
TirzepatideNot disclosed$110/mo (2.5 mg dose, promotional rate, compounded)
CoverageAll 50 states10 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Metabolyz

Graded #339 · C

Strengths

  • Three GLP-1 programs: standard semaglutide, dual-agonist tirzepatide, and a microdose protocol for near-goal or dose-sensitive patients
  • Nutrition, movement, and lifestyle coaching included in all programs at no extra charge
  • Medication compounded in licensed 503A/503B US pharmacies with temperature-controlled, unmarked direct-to-door delivery
  • Licensed provider supervision with direct messaging access and structured check-ins throughout
  • Telehealth across all 50 states; BMI 27+ eligibility (25+ with weight-related condition)

Where it loses points

  • Pricing is fully gated — not disclosed until after consultation, preventing upfront cost comparison
  • Compounded GLP-1 only — no brand-name options (Wegovy, Zepbound) available
  • No LegitScript certification or named medical leadership found on public-facing pages
  • Labs not mentioned as included — unclear whether baseline or follow-up bloodwork is offered
  • Newer brand with no external reviews, published outcomes data, or notable accreditations

Strengths

  • Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
  • GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
  • Routine labs and thousands of medications included in membership — no surprise bills
  • Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide

Where it loses points

  • 10 states only (WA, NM, AZ, UT, FL, DC, KS, OK, VA, GA) — limited vs 50-state platforms
  • Membership required to access wholesale pricing — $89/mo adds ~$1,068/yr in fixed cost
  • 503A pharmacy partners not named
  • LegitScript certification not mentioned on the site
  • Medical director and corporate legal entity not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard